Treatment of metastatic breast cancer resistant to both paclitaxel & anthracycline-containing chemotherapy regimen. In combination w/ docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relapsed during or following anthracycline-containing chemotherapy. Adjuvant therapy following the complete resection of primary tumor in patients w/ stage III colon cancer when monotherapy w/ fluoropyrimidine is preferred.
Individualized dosage. Monotherapy 1,250 mg/m2 bid for 2 wk followed by 1-wk rest period in 3-wk cycles. Adjuvant treatment Total of 6 mth (8 cycles). In combination w/ docetaxel 1,250 mg/m2 bid for 2 wk followed by a 7-day rest period, in combination w/ docetaxel 75 mg/m2 as 1-hr IV infusion every 3 wk.
Sign Out
